Menu
Peptide Database
Results
No peptides found
Featured

Use search to browse all 100+ peptides

LL-37

Cathelicidin, hCAP-18, FALL-39, CAP-18

Quick Stats
Studies 2230
Trials 95
Terminated PHASE1 INTERVENTIONAL NCT03270709

Effect of High-Dose Vitamin D3 in Smokers and Non-Smokers With and Without HIV

View on ClinicalTrials.gov Updated Dec 15, 2025

Brief Summary

Supplementation with vitamin D improves HIV+ macrophages phagocytosis in vitro. There is evidence to suggest that administering vitamin D can in fact improve immune function in individuals. The study will evaluate the impact of high dose vitamin D in HIV+ smokers' and HIV- smokers' in vivo. The primary goal is to improve innate immune host response to infection in patients already at high risk by virtue of HIV and smoking status.

Detailed Description

Tobacco smoke suppresses the lung's ability to fight infection. Smoking is three times more prevalent in the HIV+ compared to HIV- patients. Viral load was found to be significantly increased in HIV+ smokers compared to HIV+ non-smokers, suggesting that smoking enhances HIV-1 viral replication in macrophages, which contributes to disease progression. Vitamin D deficiency has been associated with increased mortality in HIV+ persons, but there is limited research on how this is impacting the health of these highest risk patients and if aggressive repletion with vitamin D can improve overall health.The study team hypothesizes that vitamin D administration will increase pathogen clearance and improve innate immune function. The proposed pre and post interventional study is designed to characterize alveolar macrophage function and lung immunity according to tobacco use and HIV status, and determine the impact of high dose oral vitamin D3 on AM phagocytic function and innate immunity.

Interventions

Name: Vitamin D3 450,000 IU orally
Type: DRUG
Description: Study subjects will receive 2 tablets of vitamin D3 for a total of 450,000 IU by mouth.

Primary Outcomes

Measure: Difference in alveolar macrophage (AM) phagocytic index between HIV+ smokers compared to HIV- non-smokers.
TimeFrame: Day 1 of the study prior to vitamin D administration.
Description: A phagocytic index will be determined by challenging AM isolated from bronchoalveolar lavage (BAL) to Staph. Aureus in vitro.
Measure: Difference in phagocytosis percent positive between HIV+ smokers compared to HIV- non-smokers, prior to vitamin D administration.
TimeFrame: Day 1 of the study prior to vitamin D administration.
Description: Difference in phagocytosis percent positive between HIV+ smokers compared to HIV- non-smokers will be calculated.
Measure: Difference in alveolar macrophage (AM) phagocytic index before and after vitamin D administration.
TimeFrame: Day 1 of the study prior to vitamin D administration, Day 7 after vitamin D administration
Description: A phagocytic index will be determined by challenging AM isolated from bronchoalveolar lavage (BAL) to Staph. Aureus in vitro.

Trial Information

NCT ID

NCT03270709

Status

Terminated

Study Type

INTERVENTIONAL

Phases

PHASE1

Sponsor

Emory University

Last Updated

December 15, 2025